# Elite Value Audit — INV_EXP_002

**Device class:** 002
**Tier:** **REJECT**
**Criteria met:** 4/12
**Fatal attacks:** 0
**Timestamp:** 2026-08-16T03:42:29.560254+00:00

## Inventive Nucleus
002 inventive concept

## Claim
```
A blood pressure monitor comprising: A) a sensor for detecting blood pressure; B) a display for displaying blood pressure readings; and C) a processor for processing blood pressure data.
```

## Economic Value Assessment
- **Customer problem:** Need for accurate, convenient, and accessible blood pressure monitoring outside clinical settings
- **Economic pain:** High healthcare costs associated with hypertension management, including frequent doctor visits, emergency care for hypertensive crises, and complications from uncontrolled blood pressure
- **Current cost:** Hypertension costs the US approximately $48.6 billion annually in direct medical expenses (EVIDENCE|CDC)
- **Value created:** Enables more frequent, accurate blood pressure monitoring outside clinical settings, potentially improving hypertension management and reducing complications
- **Who pays:** Patients (out-of-pocket), insurance companies, healthcare systems
- **Why they pay:** Reduces long-term healthcare costs by preventing complications, enables better disease management, provides valuable data for treatment decisions
- **Adoption barrier:** Requires integration with existing healthcare systems, concerns about data accuracy and reliability, need for user-friendly design for non-medical professionals
- **Value creation types:** COST_REDUCTION, IMPROVED_OUTCOMES, CONVENIENCE
- **Market size evidence:** INFERENCE
- **Market size basis:** Based on the global blood pressure monitoring market size of approximately $4.5 billion (2022) with projected growth to $7.5 billion by 2030 (Grand View Research)

## Elite Criteria Scores (12)
| # | Criteria | Met | Confidence | Reasoning |
|---|---|---|---|---|
| 1 | A_large_expensive_problem | ✓ | EVIDENCE | Hypertension costs the US approximately $48.6 billion annually in direct medical expenses, indicatin |
| 2 | B_clear_economic_buyer | ✓ | INFERENCE | Multiple potential buyers are identified: patients (out-of-pocket), insurance companies, and healthc |
| 3 | C_substantial_measurable_benefit | ✗ | HYPOTHESIS | While the invention claims to address the need for accurate, convenient, and accessible blood pressu |
| 4 | D_technically_meaningful_mechanism | ✗ | HYPOTHESIS | The claim describes only basic components (sensor, display, processor) without detailing any novel t |
| 5 | E_difficult_to_reproduce_without_the_invention | ✗ | HYPOTHESIS | The invention appears to be a standard blood pressure monitor with common components, making it easy |
| 6 | F_meaningful_structural_functional_relationship | ✗ | HYPOTHESIS | No novel structural or functional relationships between the components are described that would dist |
| 7 | G_plausible_manufacturing_path | ✓ | INFERENCE | The components (sensor, display, processor) are standard electronic components with established manu |
| 8 | H_manageable_regulatory_pathway | ✓ | INFERENCE | Blood pressure monitors are classified as medical devices with established regulatory pathways (FDA  |
| 9 | I_credible_validation_experiment | ✗ | HYPOTHESIS | No specific validation experiments are described to demonstrate the invention's effectiveness or sup |
| 10 | J_credible_patent_claim_space | ✗ | HYPOTHESIS | The claim appears overly broad and generic, covering basic components of any blood pressure monitor, |
| 11 | K_meaningful_difficulty_of_design_around | ✗ | HYPOTHESIS | Given the generic nature of the claim, competitors could easily design around it by using different  |
| 12 | L_potential_for_platform_product_expansion | ✗ | HYPOTHESIS | No indication of how this basic blood pressure monitor could be expanded into a platform or addition |
| 13 | E_difficult_to_reproduce | ✗ | HYPOTHESIS | Not assessed |
| 14 | K_meaningful_design_around_difficulty | ✗ | HYPOTHESIS | Not assessed |
| 15 | L_platform_product_expansion_potential | ✗ | HYPOTHESIS | Not assessed |

## Rejection Patterns
**Matched:** generic sensor improvement, known component substitution
**New technical effect:** NONE

## Four-Attack Destruction Test
| Attack | Strength | Can Survive | Rationale |
|---|---|---|---|
| NOVELTY_102 | NONE | ✓ | NO_NOVELTY_ATTACK_POSSIBLE. None of the provided prior-art references disclose all three claim eleme |
| OBVIOUSNESS_103 | NONE | ✓ | NO_OBVIOUSNESS_ATTACK_POSSIBLE. None of the provided prior-art references disclose any of the claim  |
| ENABLEMENT_112 | NONE | ✓ | INSUFFICIENT_EVIDENCE. The provided prior-art references do not contain enough information to assess |
| DESIGN_AROUND | MODERATE | ✓ | A competitor could design around this claim by creating a blood pressure monitoring system that elim |

## Prior-Art Search Provenance
- **Sources searched:** PATSNAP_EUREKA, LENS_SCHOLARLY, GOOGLE_PATENTS
- **Sources live:** LENS_SCHOLARLY, GOOGLE_PATENTS
- **Total hits:** 6
- **Patent family normalization:** Applied (US/WO/EP/CN/JP/KR/AU collapsed)

## Tier Reasoning
Rejection patterns matched (['generic sensor improvement', 'known component substitution']) with no new technical effect

## Honest Disclosure
- LLM calls: 4
- Elapsed: 27.8s
- All economic numbers tagged: EVIDENCE | INFERENCE | HYPOTHESIS
- Human patent lawyer review remains a separate final act
- This audit may output STRONG_CANDIDATE_FOR_FILING but NEVER LEGALLY_PATENTABLE